Related Experiment Video
Updated: Aug 22, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections
11860 Montreal Road, Pharmasset Inc. Tucker, Georgia, USA. motto@pharmasset.com
Abstract:
Several new nucleoside analogs are currently in development for the treatment of HIV-1 infections. Alovudine, amdoxovir, elvucitabine, Racivir, Reverset and SPD 754 are nucleoside reverse transcriptase inhibitors that were designed and selected in anticipation of having improved resistance, safety, compatibility and efficacy profiles. Clinical trials are demonstrating that some of these goals are being met, and that nucleoside analogs as a class of compounds remain fertile ground for finding valuable additions to current anti-retrovirus treatment regimens.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Viruses with RNA Genomes
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis

